All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Sanara MedTech Q3 revenue misses estimates on soft tissue product sales

By Reuters News


Overview

  • US surgical products maker's Q3 revenue rose 8% yr/yr but missed analyst expectations

  • Adjusted EBITDA for Q3 increased to $5.6 mln from $4.9 mln last year

  • Company posted net loss due to higher SG&A tied to pending MiMedx merger


Outlook

  • Sanara MedTech lowers 2026 net revenue guidance to $110 mln-$115 mln from $116 mln-$121 mln

  • Company expects 2026 net revenue growth of 7%-12% over 2025

  • Sanara MedTech continues regulatory review process for pending merger with MiMedx


Result Drivers

  • SOFT TISSUE PRODUCT SALES - Revenue growth was driven by higher sales of soft tissue repair products, including CellerateRX Surgical and BIASURGE

  • DISTRIBUTION NETWORK EXPANSION - Increased market penetration and expansion of independent distribution network supported revenue growth

  • MERGER-RELATED COSTS - Higher SG&A expenses, mainly from legal and advisory services tied to the pending MiMedx merger, weighed on profitability


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$28.40 mln

$29.67 mln (3 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Sanara MedTech Inc. is $35.00, about 10.7% above its November 11 closing price of $31.61

  • The stock recently traded at 62 times the next 12-month earnings vs. a P/E of 74 three months ago


Reuters Recommended Reads

  • Nov 10 - TELA Bio Q3 revenue misses analyst estimates on lower OviTex PRS volumes

  • Nov 10 - Harvard Bioscience Q3 revenue rises 8%, beats estimates

  • Nov 11 - SeaStar Medical Q3 net revenue rises on QUELIMMUNE adoption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.